A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents

Area of Science:

• Pharmacology
• Cancer Biology
• Biochemistry

Background:

• Multidrug resistance (MDR) in cancer is a significant challenge, often caused by ATP-dependent transporters like P-glycoprotein (P-gp) that efflux chemotherapy drugs.
• This efflux reduces intracellular drug concentrations, leading to treatment failure and chemoresistance in tumor cells.

Purpose of the Study:

• To present novel MDR modulating agents (MC89, MC70, PB28, IG9) that target P-gp.
• To investigate the ability of these agents to induce inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in various tumor cell lines.

Main Methods:

• Evaluation of MDR modulating agents (MC89, MC70, PB28, IG9) for their effects on P-gp.
• Assessment of iNOS expression and NO stimulation in U937, Caco-2, and MCF7-Adr tumor cell lines.
• Analysis of the compounds' ability to modulate P-gp and induce NO via iNOS.

Main Results:

• The selected compounds effectively modulated P-gp activity.
• All tested agents stimulated nitric oxide (NO) production through iNOS induction in U937, Caco-2, and MCF7-Adr cell lines.
• Demonstrated a new approach to revert MDR.

Conclusions:

• The presented compounds represent a new class of MDR reverting agents.
• This strategy offers a potential alternative to current P-gp inhibitors, overcoming their limitations.
• Highlights a novel pharmacological approach to combat chemoresistance.